143 related articles for article (PubMed ID: 16432864)
41. Comparison of minimal residual disease (MRD) estimated by flow cytometry and by real-time quantitative PCR of Wilms tumor gene 1 (WT1) transcript expression in children with acute lymphoblastic leukemia.
Chen JS; Hsiao CC; Sheen JM; Cheng CN
Leuk Res; 2007 Oct; 31(10):1351-7. PubMed ID: 17445885
[TBL] [Abstract][Full Text] [Related]
42. Azacitidine in the treatment of pediatric therapy-related myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation.
Inoue A; Kawakami C; Takitani K; Tamai H
J Pediatr Hematol Oncol; 2014 Jul; 36(5):e322-4. PubMed ID: 24608072
[TBL] [Abstract][Full Text] [Related]
43. Successful treatment of relapsed AML after allogeneic stem cell transplantation with azacitidine.
Graef T; Kuendgen A; Fenk R; Zohren F; Haas R; Kobbe G
Leuk Res; 2007 Feb; 31(2):257-9. PubMed ID: 16620971
[TBL] [Abstract][Full Text] [Related]
44. Azacytidine treatment after discontinuation of immunosuppressants in patients with myelodysplastic syndrome and relapse after allo-SCT at a single center.
Kim SY; Cho SG; Cho BS; Kim MS; Eom KS; Kim YJ; Kim HJ; Lee S; Min CK; Kim DW; Lee JW; Min WS
Bone Marrow Transplant; 2010 Aug; 45(8):1375-6. PubMed ID: 20023706
[No Abstract] [Full Text] [Related]
45. Allogeneic stem cell transplantation for myelodysplastic syndromes in children: a report from the Spanish Working Party for Blood and Marrow Transplantation in Children (GETMON).
Muñoz A; Díaz-Heredia C; Badell I; Bureo E; Gómez P; Martínez A; Verdeguer A; Pérez-Hurtado JM; Fernández-Delgado R; González-Vicent M; Maldonado MS
Pediatr Hematol Oncol; 2009; 26(5):345-55. PubMed ID: 19579081
[TBL] [Abstract][Full Text] [Related]
46. Second allogeneic stem cell transplantation in myeloid malignancies.
Hartwig M; Ocheni S; Asenova S; Wiedemann B; Zabelina T; Ayuk F; Kabisch H; Erttmann R; Kröger N; Zander AR; Bacher U
Acta Haematol; 2009; 122(4):185-92. PubMed ID: 19887774
[TBL] [Abstract][Full Text] [Related]
47. [Improvement of diabetes insipidus after allogeneic bone marrow transplantation in a patient with myelodysplastic syndrome].
Sato N; Takayama N; Kizaki M; Ikeda Y; Okamoto S
Rinsho Ketsueki; 2003 May; 44(5):318-22. PubMed ID: 12822406
[TBL] [Abstract][Full Text] [Related]
48. Bone marrow transplantation in Shwachman-Diamond syndrome.
Hsu JW; Vogelsang G; Jones RJ; Brodsky RA
Bone Marrow Transplant; 2002 Aug; 30(4):255-8. PubMed ID: 12203143
[TBL] [Abstract][Full Text] [Related]
49. Allogeneic transplantation for pediatric acute lymphoblastic leukemia: the emerging role of peritransplantation minimal residual disease/chimerism monitoring and novel chemotherapeutic, molecular, and immune approaches aimed at preventing relapse.
Pulsipher MA; Bader P; Klingebiel T; Cooper LJ
Biol Blood Marrow Transplant; 2009 Jan; 15(1 Suppl):62-71. PubMed ID: 19147081
[TBL] [Abstract][Full Text] [Related]
50. Bone marrow engraftment analysis after allogeneic bone marrow transplantation.
Van Deerlin VM; Leonard DG
Clin Lab Med; 2000 Mar; 20(1):197-225. PubMed ID: 10702903
[TBL] [Abstract][Full Text] [Related]
51. Lung function, pulmonary complications, and mortality after allogeneic blood and marrow transplantation in children.
Kaya Z; Weiner DJ; Yilmaz D; Rowan J; Goyal RK
Biol Blood Marrow Transplant; 2009 Jul; 15(7):817-26. PubMed ID: 19539213
[TBL] [Abstract][Full Text] [Related]
52. Therapy-related myelodysplastic syndrome after allogeneic BMT: successful treatment by donor lymphocyte infusions.
Roos-Weil D; Nguyen S; Uzunov M; Bories D; Chapiro E; Nguyen-Khac F; Vernant JP; Dhédin N
Bone Marrow Transplant; 2010 Sep; 45(9):1471-3. PubMed ID: 20098458
[No Abstract] [Full Text] [Related]
53. The evolution of hematopoietic SCT in myelodysplastic syndrome.
Kindwall-Keller T; Isola LM
Bone Marrow Transplant; 2009 Apr; 43(8):597-609. PubMed ID: 19252532
[TBL] [Abstract][Full Text] [Related]
54. Immunotherapy by allogeneic stem cell transplantation.
Ringdén O
Adv Cancer Res; 2007; 97():25-60. PubMed ID: 17419940
[TBL] [Abstract][Full Text] [Related]
55. Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system.
Harker-Murray PD; Thomas AJ; Wagner JE; Weisdorf D; Luo X; DeFor TE; Verneris MR; Dusenbery KE; MacMillan ML; Tolar J; Baker KS; Orchard PJ
Biol Blood Marrow Transplant; 2008 Jun; 14(6):685-92. PubMed ID: 18489994
[TBL] [Abstract][Full Text] [Related]
56. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy.
Yanada M; Sugiura I; Takeuchi J; Akiyama H; Maruta A; Ueda Y; Usui N; Yagasaki F; Yujiri T; Takeuchi M; Nishii K; Kimura Y; Miyawaki S; Narimatsu H; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
Br J Haematol; 2008 Nov; 143(4):503-10. PubMed ID: 18986386
[TBL] [Abstract][Full Text] [Related]
57. [Wilms tumor gene (WT1) as a marker for minimal residual disease in leukemia].
Hiroyasu O
Rinsho Ketsueki; 2002 Mar; 43(3):151-6. PubMed ID: 11979744
[No Abstract] [Full Text] [Related]
58. Acetazolamide-induced severe pancytopenia mimicking myelodysplasia relapse following allogeneic bone marrow transplantation.
Maclean R; O'Callaghan U; Lim SH
Bone Marrow Transplant; 1998 Feb; 21(3):309-11. PubMed ID: 9489658
[TBL] [Abstract][Full Text] [Related]
59. Quantitative monitoring of NPM1 mutations provides a valid minimal residual disease parameter following allogeneic stem cell transplantation.
Bacher U; Badbaran A; Fehse B; Zabelina T; Zander AR; Kröger N
Exp Hematol; 2009 Jan; 37(1):135-42. PubMed ID: 19100523
[TBL] [Abstract][Full Text] [Related]
60. Outcome of 93 patients with relapse or progression following allogeneic hematopoietic cell transplantation.
Kurosawa S; Fukuda T; Tajima K; Saito B; Fuji S; Yokoyama H; Kim SW; Mori S; Tanosaki R; Heike Y; Takaue Y
Am J Hematol; 2009 Dec; 84(12):815-20. PubMed ID: 19899134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
